Protocol · Pediatric Health
Retinopathy of Prematurity (ROP) Prevention Support Protocol
Omega-3 Fatty Acids (DHA) and Vitamin E are the core of this stack, with 5 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Retinopathy of Prematurity (ROP) Prevention Support.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
7 supplements · none graded yet · 1 confirmed study
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Omega-3 Fatty Acids (DHA) | Amount listed: 40–60 mg/kg/day DHA in enteral nutrition (NICU-managed) | DHA essential for retinal development; premature infants miss third-trimester DHA transfer; may reduce ROP risk | Not graded yet | |
| Vitamin E | Amount listed: NICU-managed supplementation (careful dosing required) | Antioxidant; protects retinal tissue from oxidative damage; studied for ROP prevention | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Vitamin A | Amount listed: NICU-managed (5,000 IU IM three times weekly in very low birth weight infants) | Essential for eye development and function; premature infants often deficient | Not graded yet | |
| Inositol | Amount listed: NICU-managed supplementation | Cell signaling molecule important for lung and eye development; studied for ROP prevention | Not graded yet | |
| Carotenoids (Lutein/Zeaxanthin) | Amount listed: 0.14 mg lutein + 0.006 mg zeaxanthin per kg/day (NICU-managed) | Macular pigments that protect retina from oxidative damage; naturally transferred in breast milk | Not graded yet | |
| Zinc | Amount listed: NICU-managed supplementation (1–2 mg/kg/day) | Essential for retinal function and vitamin A metabolism; premature infants at risk of deficiency | Not graded yet | |
| Caffeine | Amount listed: Standard caffeine citrate dosing for apnea of prematurity (NICU-managed) | Given for apnea of prematurity; incidentally reduces ROP risk through unknown mechanisms | Not graded yet | |
Confirmed studies for Caffeine (titles as PubMed lists them) | ||||
How this protocol works
In plain language
Retinopathy of Prematurity (ROP) is an eye disease that affects premature babies, particularly those born before 31 weeks or weighing less than 1500 grams. In the womb, retinal blood vessels normally develop and reach the edge of the retina by about 36-40 weeks. When a baby is born prematurely, this development is incomplete. The abnormal blood vessel growth that follows can cause scarring, retinal detachment, and potentially blindness.
CRITICAL: ROP is a serious condition that requires expert NICU and ophthalmologic care. All at-risk premature infants receive regular eye examinations. Treatment when needed includes laser therapy, injections (anti-VEGF), or surgery. The supplements listed here are administered under strict medical supervision in the NICU setting and are NOT for home use. This information is for educational purposes about current research.
RISK FACTORS: Very low birth weight (<1500g), gestational age <31 weeks, supplemental oxygen exposure, sepsis, blood transfusions, respiratory distress syndrome, and other complications of prematurity.
DHA (Omega-3)* is critical for retinal development. Premature infants miss the third-trimester transfer of DHA from mother to baby. Supplementation in enteral feeds may help reduce ROP risk.
Vitamin E* is an antioxidant that may protect the developing retina from oxygen-related damage. Must be carefully dosed as high levels can be harmful.
Vitamin A* is essential for eye development and is often deficient in premature infants.
Inositol* is a naturally occurring compound important for surfactant function and eye development.
Lutein/Zeaxanthin* are macular pigments that protect the retina. They are naturally present in breast milk.
Caffeine* is routinely given for apnea of prematurity and has been found to incidentally reduce ROP risk.
Expected outcomes: ROP screening and treatment have dramatically improved outcomes. Most mild ROP resolves without treatment. With appropriate care, severe visual impairment from ROP has decreased significantly.